Comparative chemical profiling, cholinesterase inhibitions and anti-radicals properties of essential oils from Polygonum hydropiper L: A Preliminary anti- Alzheimer’s study

[1]  A. Zeb,et al.  Phenolic, flavonoid contents, anticholinesterase and antioxidant evaluation of Iris germanica var; florentina , 2016, Natural product research.

[2]  Farhan,et al.  1,1-Diphenyl,2-picrylhydrazyl free radical scavenging, bactericidal, fungicidal and leishmanicidal properties of Teucrium stocksianum , 2015, Toxicology and industrial health.

[3]  M. Ayaz,et al.  Synthesis, anticholinesterase and antioxidant potentials of ketoesters derivatives of succinimides: a possible role in the management of Alzheimer’s , 2015, Chemistry Central Journal.

[4]  A. Zeb,et al.  Anticholinesterse and antioxidant investigations of crude extracts, subsequent fractions, saponins and flavonoids of atriplex laciniata L.: potential effectiveness in Alzheimer’s and other neurological disorders , 2015, Biological Research.

[5]  M. Ayaz,et al.  Antioxidant and anticholinesterase investigations of Rumex hastatus D. Don: potential effectiveness in oxidative stress and neurological disorders , 2015, Biological Research.

[6]  A. Zeb,et al.  Investigations of anticholinestrase and antioxidant potentials of methanolic extract, subsequent fractions, crude saponins and flavonoids isolated from Isodon rugosus , 2014, Biological Research.

[7]  R. Vassar.  BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[8]  M. Junaid,et al.  Heavy metals analysis, phytochemical, phytotoxic and anthelmintic investigations of crude methanolic extract, subsequent fractions and crude saponins from Polygonum hydropiper L , 2014, BMC Complementary and Alternative Medicine.

[9]  M. Junaid,et al.  Phenolic contents, antioxidant and anticholinesterase potentials of crude extract, subsequent fractions and crude saponins from Polygonum hydropiper L , 2014, BMC Complementary and Alternative Medicine.

[10]  Jian-Dong Huang,et al.  Berberine ameliorates β-amyloid pathology, gliosis, and cognitive impairment in an Alzheimer's disease transgenic mouse model , 2012, Neurobiology of Aging.

[11]  I. Bassolé,et al.  Chemical composition and antimicrobial activity of Cymbopogon citratus and Cymbopogon giganteus essential oils alone and in combination. , 2011, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[12]  E. Sakai,et al.  Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways. , 2008, European journal of pharmacology.

[13]  Cheorl-Ho Kim,et al.  Polygonum cuspidatum, compared with baicalin and berberine, inhibits inducible nitric oxide synthase and cyclooxygenase-2 gene expressions in RAW 264.7 macrophages. , 2007, Vascular pharmacology.

[14]  Y. Chan,et al.  Chinese herbs and herbal extracts for neuroprotection of dopaminergic neurons and potential therapeutic treatment of Parkinson's disease. , 2007, CNS and Neurological Disorders - Drug Targets.

[15]  Peter J Houghton,et al.  Acetylcholinesterase inhibitors from plants. , 2007, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[16]  R. Adams,et al.  Identification of Essential Oil Components By Gas Chromatography/Mass Spectrometry , 2007 .

[17]  T. Saido,et al.  Berberine alters the processing of Alzheimer's amyloid precursor protein to decrease Abeta secretion. , 2007, Biochemical and biophysical research communications.

[18]  Xia Li,et al.  Neuroprotective effects of Polygonum multiflorum on nigrostriatal dopaminergic degeneration induced by paraquat and maneb in mice , 2005, Pharmacology Biochemistry and Behavior.

[19]  M. Heinrich,et al.  Galanthamine from snowdrop--the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. , 2004, Journal of ethnopharmacology.

[20]  M. T. C. Trevisan,et al.  Seleção de plantas com atividade anticolinasterase para tratamento da doença de Alzheimer , 2003 .

[21]  J. Cummings.  Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. , 2003, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[22]  E. Giacobini,et al.  Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit , 2002, Journal of Neural Transmission.

[23]  M. Mesulam,et al.  Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine , 2002, Neuroscience.

[24]  C. Ballard,et al.  Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition , 2002, European Neurology.

[25]  P. Tariot,et al.  A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting , 2001, Journal of the American Geriatrics Society.

[26]  L. D. Bari,et al.  Antioxidant principles from Bauhinia tarapotensis. , 2001, Journal of natural products.

[27]  L. Schneider.  Treatment of Alzheimer's disease with cholinesterase inhibitors. , 2001, Clinics in geriatric medicine.

[28]  Xiaoxiang Zhu,et al.  A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase , 2001, Current medical research and opinion.

[29]  L. Wilkins.  Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension , 2000, Neurology.

[30]  N. Perry,et al.  In‐vitro Inhibition of Human Erythrocyte Acetylcholinesterase by Salvia lavandulaefolia Essential Oil and Constituent Terpenes , 2000, The Journal of pharmacy and pharmacology.

[31]  E. Peskind,et al.  Galantamine in AD , 2000, Neurology.

[32]  C. Rice-Evans,et al.  Antioxidant activity applying an improved ABTS radical cation decolorization assay. , 1999, Free radical biology & medicine.

[33]  P Dal-Bianco,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. , 1999, BMJ.

[34]  Y. Agid,et al.  Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw , 1999 .

[35]  J. Salonen,et al.  Natural antioxidants and anticarcinogens in nutrition, health and disease: proceedings of the Second International Conference on Antioxidants and Anticarcinogens in Nutrition. , 1999 .

[36]  F. Luscombe,et al.  Safety of Tacrine: Clinical Trials, Treatment IND, and Postmarketing Experience , 1998, Alzheimer disease and associated disorders.

[37]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[38]  R. Nitsch.  From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[39]  H. Sugimoto,et al.  Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine hydrochloride and related compounds. , 1995, Journal of medicinal chemistry.

[40]  B. Halliwell,et al.  Free radicals, antioxidants, and human disease: curiosity, cause, or consequence? , 1994, The Lancet.

[41]  P. Watkins,et al.  Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. , 1994, JAMA.

[42]  P. Solomon,et al.  A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. , 1994, JAMA.

[43]  Gastone G. Celesia,et al.  A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .

[44]  C. Geula,et al.  Neuroglial cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability , 1993, Annals of neurology.

[45]  H. Soreq,et al.  Human Cholinesterases and Anticholinesterases , 1993 .

[46]  J. Klaunig,et al.  Prevention of cytotoxicity and inhibition of intercellular communication by antioxidant catechins isolated from Chinese green tea. , 1989, Carcinogenesis.

[47]  E. Perry,et al.  CHANGES IN BRAIN CHOLINESTERASES IN SENILE DEMENTIA OF ALZHEIMER TYPE , 1978, Neuropathology and applied neurobiology.

[48]  P. Davies,et al.  SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE , 1976, The Lancet.

[49]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[50]  Em Mead,et al.  Society for Neuroscience Annual Meeting , 2009 .

[51]  Ming-Fu Wang,et al.  Long-term administration of Polygonum multiflorum Thunb. reduces cerebral ischemia-induced infarct volume in gerbils. , 2003, The American journal of Chinese medicine.

[52]  P. Ferry,et al.  Nutritional Status and Well Being. Is There a Relationship Between Body Mass Index and the Well-being of Older People? , 2001 .

[53]  J. Salonen,et al.  Natural antioxidants and anticarcionogens in nutrition, health and disease. , 1999 .

[54]  G. Porta,et al.  Essential oils from two Peruvian Satureja species , 1998 .

[55]  Jorge D. Pamplona Roger,et al.  Encyclopedia of medicinal plants , 1998 .

[56]  T. Thomsen,et al.  Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. , 1990, Life sciences.

[57]  S. Barlow.  Toxicological Aspects of Antioxidants Used as Food Additives , 1990 .

[58]  D. Maulik,et al.  Characterization of a cocaine binding protein in human placenta. , 1990, Life sciences.

[59]  E. Perry.  The cholinergic hypothesis--ten years on. , 1986, British medical bulletin.